Edison Investment Research - RXI Pharmaceuticals Corp (RXII) Expanding into immuno-oncology

Report

Edison Investment Research

Maxim Jacobs

Expanding into immuno-oncology

RXi recently announced that it has entered into an exclusive option agreement to acquire MirImmune, an early-stage private company focusing on immune checkpoint modulation, in exchange for a share amount equal to 19.99% of RXi’s outstanding stock plus milestones. MirImmune had previously licensed RXi’s sd-rxRNA technology in March 2015 and has since selected six lead compounds, which will be used alone or in combination to develop cell therapy to treat cancer. The first cell therapy will likely reach the clinic in 2018. RXi also announced a planned capital raise. If unable to raise capital, its cash runway extends only into Q217.

25/10/2016 6 EN

Underlying

RXI Pharmaceuticals Corp

See profile

US74979C5013 United States

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Maxim Jacobs

Other Reports on these Companies

Edison Investment Research

Update: Samcyprone data at AAD

At the American Academy of Dermatology (AAD) Summer Meeting, data from a pilot study of Samcyprone (diphenylcyclopropenone ointment) in the treatment of common warts was presented. Overall, 38.1% of subjects saw a greater than 50% clearance over seven weeks compared to 6.7% in the placebo arm (p=0.051). On a per-protocol basis, 47.6% saw greater than 50% clearance (p=0.011). A Phase IIa with an improved formulation and 10-week treatment period was initiated in December 2015, with enrolment expected to be completed by year-end 2016.

August 3, 2016 August 3, 2016 5 EN

Edison Investment Research

Update: Spotlight on cosmetic product development

RXi Pharmaceuticals (RXi) continues to make solid progress with its development pipeline. We anticipate one of two promising cosmeceutical candidates to enter human testing this year, moving forward on an expedited pathway for potential launch in 2019. We also expect data in H216 in all lead projects including RXI-109 in dermal scarring and in retinal scarring in wet AMD, and Samcyprone in cutaneous warts.

April 18, 2016 April 18, 2016 7 EN

discoverIE Group - FY24 EPS in line; good margin progress

discoverIE anticipates reporting FY24 underlying EPS in line with board expectations. After a period in mid-FY24 of working down inventory, customers appear to be reverting to normal ordering patterns, with Q424 organic revenue growth of 2% y-o-y and 11% q-o-q and a strong pipeline of design wins at year-end. We have revised our forecasts to reflect lower revenue, partly due to a disposal, but maintain our profit forecasts, which results in operating margin expansion in FY24 and FY25.

10h / 3m 10h / 3m 1 EN

Sean Conroy

Sean Conroy

Ultimovacs - Steadfast commitment to UV1 progression

Despite the recent setback with the INITIUM trial (first-line treatment of patients with unresectable or metastatic malignant melanoma), Ultimovacs has reinstated its commitment to press on with its clinical development of its cancer vaccine, UV1, across other target indications. The principal near-term focus will be on the anticipated results of Phase II FOCUS (head and neck cancer) and DOVACC (ovarian cancer) trials in Q324 and H125, respectively, and will inform its subsequent strategic direction. To remain funded to these milestones, the company has enforced stringent cost control measures...

April 18, 2024 April 18, 2024 1 EN

Sean Conroy

Sean Conroy

OSE Immunotherapeutics - AbbVie deal clears antitrust hurdle

OSE has announced that its licence agreement with AbbVie has cleared antitrust review and has become effective. As previously noted, this is expected to support OSE’s runway extension into 2026, past key milestones and readouts for in-house assets Tedopi (non-small cell lung cancer, US Phase III trials expected to commence in Q224) and Lusvertikimab (ulcerative colitis, Phase II readouts expected in mid-2024). Following the Federal Communications Commission (FCC) mandatory waiting period, OSE is expected to receive the negotiated US$48m upfront payment from AbbVie imminently, as part of its gl...

April 18, 2024 April 18, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Expanding into immuno-oncology

Update: Samcyprone data at AAD

Update: Spotlight on cosmetic product development

discoverIE Group - FY24 EPS in line; good margin progress

Ultimovacs - Steadfast commitment to UV1 progression

OSE Immunotherapeutics - AbbVie deal clears antitrust hurdle

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe